Clinical Trial: Mavacamten in Obstructive Hypertrophic Cardiomyopathy

U.S., Sept. 12 -- ClinicalTrials.gov registry received information related to the study (NCT07168655) titled 'Mavacamten in Obstructive Hypertrophic Cardiomyopathy' on July 23.

Brief Summary: The purpose of this study is to evaluate the real-world outcomes of individuals diagnosed with obstructive hypertrophic cardiomyopathy (oHCM) treated with mavacamten at the Hospital of The University of Pennsylvania in the US

Study Start Date: Feb. 21, 2023

Study Type: OBSERVATIONAL

Condition: Obstructive Hypertrophic Cardiomyopathy (oHCM)

Intervention: DRUG: Mavacamten

According to the product label

Recruitment Status: COMPLETED

Sponsor: Bristol-Myers Squibb

Disclaimer: Curated by HT Syndication....